OneDigital Investment Advisors LLC Cuts Stock Holdings in Bristol Myers Squibb Company $BMY

OneDigital Investment Advisors LLC lowered its position in Bristol Myers Squibb Company (NYSE:BMY) by 7.1% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 102,842 shares of the biopharmaceutical company’s stock after selling 7,872 shares during the period. OneDigital Investment Advisors LLC’s holdings in Bristol Myers Squibb were worth $5,926,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. waypoint wealth counsel purchased a new stake in shares of Bristol Myers Squibb during the 4th quarter worth $1,194,000. Life Cycle Investment Partners Ltd acquired a new stake in shares of Bristol Myers Squibb in the fourth quarter valued at about $34,406,000. Lazard Asset Management LLC grew its position in Bristol Myers Squibb by 23.7% during the first quarter. Lazard Asset Management LLC now owns 1,924,036 shares of the biopharmaceutical company’s stock worth $116,693,000 after buying an additional 368,193 shares during the period. Axxcess Wealth Management LLC increased its holdings in Bristol Myers Squibb by 27.4% in the fourth quarter. Axxcess Wealth Management LLC now owns 98,665 shares of the biopharmaceutical company’s stock valued at $5,322,000 after buying an additional 21,196 shares in the last quarter. Finally, Asset One Wealth Management LLC purchased a new position in Bristol Myers Squibb in the fourth quarter valued at about $4,075,000. Institutional investors and hedge funds own 76.41% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently commented on BMY. Truist Financial reissued a “buy” rating and set a $70.00 price target (up from $65.00) on shares of Bristol Myers Squibb in a research note on Friday, July 31st. BMO Capital Markets reaffirmed a “market perform” rating on shares of Bristol Myers Squibb in a report on Monday, July 27th. Raymond James Financial began coverage on Bristol Myers Squibb in a report on Wednesday, August 5th. They issued a “strong-buy” rating on the stock. Royal Bank Of Canada lifted their price target on Bristol Myers Squibb from $60.00 to $64.00 and gave the stock a “sector perform” rating in a research note on Friday, July 31st. Finally, Citigroup reissued a “neutral” rating and issued a $70.00 price objective (up from $66.00) on shares of Bristol Myers Squibb in a research note on Monday, August 3rd. One investment analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Bristol Myers Squibb has a consensus rating of “Moderate Buy” and an average price target of $66.06.

Bristol Myers Squibb Trading Up 1.4%

Bristol Myers Squibb stock opened at $64.71 on Tuesday. The stock has a 50-day moving average price of $59.75 and a 200 day moving average price of $59.06. Bristol Myers Squibb Company has a 52 week low of $42.52 and a 52 week high of $68.10. The stock has a market cap of $132.18 billion, a PE ratio of 14.25, a P/E/G ratio of 0.17 and a beta of 0.22. The company has a current ratio of 1.53, a quick ratio of 1.38 and a debt-to-equity ratio of 1.89.

Bristol Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.60 by $0.44. The company had revenue of $12.97 billion for the quarter, compared to analyst estimates of $11.74 billion. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. The firm’s quarterly revenue was up 5.7% on a year-over-year basis. During the same period in the prior year, the firm earned $1.46 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. Equities research analysts predict that Bristol Myers Squibb Company will post 6.95 earnings per share for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, August 3rd. Shareholders of record on Thursday, July 2nd were paid a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 3.9%. The ex-dividend date of this dividend was Thursday, July 2nd. Bristol Myers Squibb’s dividend payout ratio is currently 55.51%.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.